Steven Gillis
Steven Gillis is Managing Director at ARCH Venture Partners.
University of Washington Launches Vilya with $50 Million to Develop Membrane-Permeable Peptide Drugs
University of Washington researchers developed custom peptides that penetrate cell membranes, enabling a new class of drugs with combined benefits of small molecules and protein therapeutics. They founded Vilya, backed by $50 million from Arch Venture Partners, to commercialize this drug platform described in Cell.
Mozart Therapeutics Raises $55M Series A to Advance CD8 Treg Modulators into Clinic
Mozart Therapeutics raised $55 million in a Series A round to develop first‑in‑class CD8 Treg modulators aimed at restoring immune balance and creating disease‑modifying treatments for autoimmune and inflammatory diseases.
Fred Hutch spinout Faraday Pharmaceuticals raises $25M (up to $30M) to advance iodide drug preventing reperfusion injury and muscle loss
Faraday Pharmaceuticals, a Fred Hutch spinout, has raised $25 million (potentially up to $30 million) to develop an iodide-based drug to prevent reperfusion injury after heart attacks and ultimately limit skeletal muscle loss in stressed or bedridden patients.
See all 5 stories, episodes and videos about Steven Gillis.
Seattle Flow is free for everyone.
- Claim and edit your profile
- Get alerts about you, your company, and anything else you care about
- Access the most comprehensive investor list in Seattle
- Join the conversation on news, podcasts, and events
Organizations
-
ARCH Venture Partners Managing Director · current
-
Faraday Pharmaceuticals Director 2017–present · current
-
OncoResponse Director 2017–2023 · past